Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Regado Biosciences's Total Stockholders Equity for the quarter that ended in Jun. 2016 was $19.76 Mil. Regado Biosciences's Total Assets for the quarter that ended in Jun. 2016 was $44.64 Mil.
Therefore, Regado Biosciences's Equity to Asset Ratio for the quarter that ended in Jun. 2016 was 0.44.
The historical rank and industry rank for Regado Biosciences's Equity-to-Asset or its related term are showing as below:
RGDO'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.44 Med: 0.51 Max: 0.57
Current: 0.44
During the past 5 years, the highest Equity to Asset Ratio of Regado Biosciences was 0.57. The lowest was 0.44. And the median was 0.51.
RGDO's Equity-to-Asset is not ranked
in the Biotechnology industry.
Industry Median: 0.66
vs RGDO: 0.44
Regado Biosciences Equity-to-Asset Historical Data
The historical data trend for Regado Biosciences's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Regado Biosciences's Equity-to-Asset
For the Biotechnology subindustry, Regado Biosciences's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Regado Biosciences's Equity-to-Asset Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Regado Biosciences's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Regado Biosciences's Equity-to-Asset falls into.
Regado Biosciences Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Regado Biosciences's Equity to Asset Ratio for the fiscal year that ended in Dec. 2015 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Regado Biosciences Equity-to-Asset Related Terms
Thank you for viewing the detailed overview of Regado Biosciences's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Regado Biosciences (Regado Biosciences) Business Description
Regado Biosciences Inc was incorporated in Delaware under the name Quartet Biosciences, Inc. in December 2001 and changed its name to Regado Biosciences, Inc. in March 2003. It is a biopharmaceutical company. The Company is engaged in the discovery and development of antithrombotic drug systems for acute and sub-acute cardiovascular indications. The Company's product candidates consists of a two-component system: an aptamer and its specific active control agent. The aptamer is administered first and achieves its therapeutic effect within minutes. When the therapeutic effect of the aptamer is no longer needed, the control agent is administered to rapidly and precisely reduce or eliminate it. The level of reduction is determined by the amount of control agent given compared to the aptamer dose. The Company's product candidate, REG1, consists of pegnivacogin, a highly potent and selective anticoagulant, and anivamersen, its specific active control agent. The Company is developing REG1 as an anticoagulant for use in patients with cardiovascular conditions undergoing percutaneous coronary intervention, or PCI, a hospital-based procedure used to mechanically open or widen obstructed coronary arteries.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
RGDO has been successfully added to your 